Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10757461 | 0.81 | — | — | |
| SCHEMBL154677 | 0.79 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL3822361 | 0.79 | THRB (0.32) | — | |
| SCHEMBL991212 | 0.77 | — | — | |
| SCHEMBL154678 | 0.77 | — | — | |
| SCHEMBL826515 | 0.77 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL9296094 | 0.76 | — | — | |
| SCHEMBL7840759 | 0.76 | ADRA2A (0.32) | — | |
| SCHEMBL7879297 | 0.76 | — | — | |
| SCHEMBL10463633 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119175008-A | Anti-pollution reverse osmosis membrane and preparation method thereof | 湖南澳维科技股份有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-118307474-A | Contracture medicine with synergistic analgesic effect and preparation method and application thereof | 江苏海洋大学 | 2024-07-09 | — | — | CN | claimed |
| CN-113087765-B | Preparation method of mustard gas peptide adduct | 中国人民解放军军事科学院军事医学研究院 | 2022-10-11 | — | — | CN | claimed |
| CN-115124447-A | Preparation method of 3-azetidinone hydrochloride | 山东诚创蓝海医药科技有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-112876554-B | Fluoxetine antigen and preparation method thereof | 杭州隆基生物技术有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-110606926-B | Auxiliary agent for enhancing water resistance of polyurethane and preparation method thereof | 成都硅宝科技股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-112876554-A | Fluoxetine antigen and preparation method thereof | 杭州隆基生物技术有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-110981949-B | Preparation method of ketamine antigen | 杭州隆基生物技术有限公司 | 2020-11-06 | — | — | CN | claimed |
| CN-111875512-A | Secondary amine and amide podand ether ligand containing ether bond and preparation method and application thereof | 四川大学 | 2020-11-03 | — | — | CN | claimed |
| CN-110981949-A | Preparation method of ketamine antigen | 杭州隆基生物技术有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-12473251-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-18 | — | — | US | disclosed |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LIGACHEM BIOSCIENCES INC. (KR) | 2025-08-19 | — | — | US | disclosed |
| CN-119504882-A | Synthesis method of GalNAc derivative | 北京炫景瑞医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119431406-A | Tricyclic compounds and medical uses thereof | 正大天晴药业集团股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025033387-A1 | PRODUCTION METHOD FOR GLYCOLIPID DERIVATIVES, SYNTHETIC INTERMEDIATES FOR SAME, AND CRYSTALS OF SAME | ＥＡファーマ株式会社 | 2025-02-13 | — | — | WO | disclosed |
| US-4487769-A | ANTITUMOR AGENTS;MITOMYCIN DERIVATIVES | BRISTOL-MYERS COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
| US-4479947-A | Oral absorption enhancement of carboxylic acid pharmaceuticals using (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl ester group | MERCK & CO., INC. (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0083039-A1 | 4-Cyano-2-azetidinones and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1983-07-06 | — | — | EP | disclosed |
| EP-0070013-A1 | Oral absorption enhancement of carboxylic acid pharmaceuticals using (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl ester group | MERCK & CO. INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0053815-A1 | 2-Oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473251-B2 | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine | KHK, GCK, BCKDK | ALDH1A1 3445/4885 |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | ALDH1A1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.